New monkeypox vaccine JT118 enters first human safety trial
NCT ID NCT07495202
First seen Mar 27, 2026 · Last updated May 09, 2026 · Updated 6 times
Summary
This early-stage study tests a new monkeypox vaccine called JT118 in 180 healthy adults aged 18 to 59. The main goal is to check if the vaccine is safe and triggers an immune response. Participants will receive one, two, or three doses and be monitored for side effects and immune markers for up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTH VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Third People's Hospital
Shenzhen, Guangdong, 518112, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.